For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- R&D Operations Start for Diagnostic Products: Alfresa Pharma
June 11, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
June 11, 2013
- Ethical, OTC Drug Sales Up 1.3% and 9.5%: Crecon Report
June 10, 2013
- Bayer to File Eylea for mCNV in Japan Later This Year
June 10, 2013
- Taiho’s TS-1 Non-Inferior to UFT/LV in Resected Colon Cancer Patients: PIII Study
June 7, 2013
- Nichi-Iko Announces Launching of Authorized Generic of Allegra in June; Is Late Launch Part of Sanofi’s Carefully Worked-out Strategy?
June 7, 2013
- Use of Contract MRs on the Rise among Smaller Drug Makers; JCSOA’s Goal of “5,000 CMRs by 2015” May Be Realistic
June 7, 2013
- Zeria, Astellas Launch World’s First FD Treatment
June 6, 2013
- DSP Completes Construction of New Chemical Research Facility in Osaka
June 6, 2013
- AZ Decides Not to Proceed with Regulatory Filings for Novel Oral RA Treatment Fostamatinib
June 6, 2013
- Nihon Chouzai to Increase Its Subsidiary’s Generic Production Capacity
June 5, 2013
- Takeda Unveils Interim Data from ADCETRIS PI Study in Pediatric Patients
June 5, 2013
- Fujifilm, Dr. Reddy’s Terminate Plan for Joint Venture for Generics
June 5, 2013
- Novartis Pharma to Cut Pay of 9 Top Officials and Suspend Promotion of Ethical Drugs for 5 Days Over Diovan Scandal
June 5, 2013
- Nippon Chemiphar to Outsource Production to Vietnam Next Spring
June 5, 2013
- BMKK, Ono Start Copromotion of Orencia following Lifting of All-Case Surveillance
June 5, 2013
- Four Drug Makers File Their Anticancer Drugs for FOLFIRINOX Therapy for Pancreatic Cancer
June 4, 2013
- Japan Pharma Leaders: Drug Development via GHIT Fund Hoped to Fuel Economic Growth in Developing World
June 4, 2013
- Fujifilm Initiates PI Study of MDS Treatment FF-10501 in Japan
June 4, 2013
- AZ to Assess Possibility of EGFR Mutation Testing via Blood in Japan-Europe Study
June 3, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…